Ventripoint Diagnostics, Inc. (VPTDF) Seeks to Expand AngeloVMS™ Applications, Triple Sales by 2014

Ventripoint Diagnostics is the creator of what company management believes to be the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company created the blueprint to achieve its application expansion and goals for continued financial growth, supported by key management.

The first applications of the company’s Angelo (VMS™) analysis system are congenital heart disease and pulmonary arterial hypertension. Ventripoint has been granted Canada and Europe (CE Mark) approval for the sale of VMS and is awaiting the U.S.-FDA marketing clearance as well.

VMS was developed to address several issues associated with current heart diagnostics and holds several advantages over an MRI scan. VMS procedure time is 15 minutes and is much cheaper compared to MRI or CT, in part because of the reduced office visit time. The tool eliminates the requirement of general anesthetic for children, a lengthy heart analysis process, and the need for a second trip to the hospital.

As of March 2013, Ventripoint had installed VMS in numerous research centers (10 in Europe, four in Canada, and 12 in the United States) and forecasts full-year 2013 revenue between $3 million – $5 million. The company’s goal by the year 2014 is to triple revenue to $10 million – $15 million.

Raising awareness and generating sales are obvious keys to achieving these sales goals, and in support of this, the company later this month will travel to Minneapolis, Minn., for the 24th Annual Scientific Sessions (ASE2013) where it will host a booth to present its products to attendees.

Ventripoint in December will also hold a booth at EuroEcho2012 in Istanbul, Turkey, an annual meeting that this year will focus on heart failure and imaging in interventional cardiology. Scientific minds from around the world will convene to discuss the latest research and clinical findings on the broader spectrum of echocardiography as well as other cardiovascular imaging modalities.

CEO George Adams heads the company as a serial entrepreneur and financier. Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies, and Centres of Excellence.

The company in March appointed Ellen Briant as its CFO to head the company’s financial strategy as it continues to launch new products, build revenues, and seek out and establish partnerships to further grow the company.

For more information, visit

Please see disclaimer on the QualityStocks website: